AbCellera Biologics Inc. ABCL Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost.
The official record: AbCellera Biologics Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s effective income tax rate reconciliation nondeductible expense share based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s effective income tax rate reconciliation nondeductible expense share based compensation cost?
- AbCellera Biologics Inc. (ABCL) reported effective income tax rate reconciliation nondeductible expense share based compensation cost of -6.6% in Q4 2025.
- What does effective income tax rate reconciliation nondeductible expense share based compensation cost mean?
- Indicates the percentage point impact of non-deductible share-based compensation on the company's effective income tax rate. It demonstrates how equity-based incentive structures affect the company's tax efficiency.